Respiratory

In the third installment of RSV Roundtable, our panel discusses the impact nirsevimab has had this RSV season.

The unprecedented demand for nirsevimab-alip has resulted in a dramatic uptake in production of this RSV vaccine.

In the second installment of RSV Roundtable, our panel explains how they are educating patients and parents when it comes to RSV, vaccines and preventive measures, and limited treatment availability.

Last year’s historic RSV season left many wondering if this was going to become a recurring trend. Physicians weigh in on what they are seeing at their institutions in terms of infection rates.

Tina Tan, MD, FAAP, FIDSA, FPIDS, explains that the recent uptick in pediatric pneumonia cases across the country, which some have called "white lung syndrome," is nothing new, and there is no cause for panic.

Investigators asked the children’s parents about the history of musculoskeletal-related disease, observed the children’s gait, and performed physical examinations.

The federal agencies announced the availability of additional doses of nirsevimab-alip (Beyfortus; Sanofi) for infants at high-risk of infection.

A new study shows that a mother's inflammatory diet, before birth of the infant, can have an impact on a child's wheeze trajectory.

The importance of follow-up meetings for youth patients discharged from emergency departments is highlighted by new research.

A sneak peek at some of the most exciting sessions at this year's American Academy of Pediatrics national conference.

New immunizations for RSV are making this respiratory infection preventable in ways it never was before. Here is the latest news on recent approvals and future outlooks.

*Co-first authorship was earned, as each equally contributed to the methodical and rigorous review of the literature, writing, and editing of this article.

As we head into cold and flu season, researchers try to answer the question of what physical interventions are best for infection prevention.

A new study notes that coinfections, amongst other issues, can complicate diagnosis and management of respiratory infections in children.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

In collaboration with Contemporary Pediatrics, Contemporary OB/GYN, and Contagion, Tina Tan, MD, FAAP, FIDSA, FPIDS, discusses the benefits of having new tools to fight RSV in infants, potential vaccine hesitancy, and RSV trends currently being observed.

Ahead of the first fall and winter virus seasons in which vaccines are available for COVID-19, influenza, and respiratory syncytial virus (RSV), the Centers for Disease Control and Prevention is recommending Pfizer’s maternal vaccine to protect newborns from severe RSV illness.

According to a recent C.S. Mott Children’s Hospital National Poll on Children’s Health, the recent wildfires and extreme weather events that are creating poor or unhealthy air quality are also causing concern for parents in regards to their children's health.

This new data expands upon limited current research on environmental elements that contribute to the extensive variation in symptoms and infection frequency seen in children.

The federal agency says infants of a certain age should receive this monoclonal antibody to protect against the virus.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Due to increased RSV activity observed in Southeastern regions of the United States, the Centers for Disease Control and Prevention (CDC) has issued an official Health Alert Network Health Advisory. The CDC recommends that clinicians prepare to implement recently FDA-approved prevention methods.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

From a virus that had no treatment options, to one that may be prevented in two different modalities, clinicians are hoping to see a reduction in respiratory syncytial virus (RSV) incidence rates, starting this fall.

Donna Hallas PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, reflects on an article about wildfire inhalation and children, published in our August 2023 issue, and provides pediatric nurse practitioners some tips if they encounter these types of cases.

Investigators of a study published in Pediatrics examined whether a 30-minute exposure to outdoor air (< 50 °F) would improve symptoms of mild to moderate croup.

Tina Tan, MD, FAAP, FIDSA, FPIDS, discusses what Pfizer's recently FDA-approved RSV vaccine means for infants ahead of the traditional RSV season.

Approved for use at 32 weeks through 36 weeks gestation, Pfizer’s maternal respiratory syncytial vaccine (Abrysvo), is delivered through a single dose injection to the muscle, and is the first vaccine for use in pregnant individuals to prevent lower respiratory tract disease (LRTD) and severe LRTD because of RSV in infants (birth to 6 months).

The recommendation from the American Academy of Pediatrics (AAP) follows the unanimous recommendation by the CDC advisory group for routine use of nirsevimab in newborns and infants younger than 8 months born into or entering their first RSV season.

Study authors stated that several past studies have put focus on training an independent model separately for lung or heart sound diagnosis but note that having a model that can “simultaneously detect abnormal lung and heart sounds,” is essential.